

PRODUCT INFORMATION




Ozanimod

Item No. 19922

CAS Registry No.: 1306760-87-1
Formal Name: 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile

MF: C₂₃H₂₄N₄O₃
FW: 404.5
Purity: ≥98%
UV/Vis.: λ_{max}: 210, 229, 275 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ozanimod is supplied as a crystalline solid. A stock solution may be made by dissolving the ozanimod in the solvent of choice, which should be purged with an inert gas. Ozanimod is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ozanimod in these solvents is approximately 0.2, 1, and 2 mg/ml, respectively.

Ozanimod is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ozanimod should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Ozanimod has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Ozanimod is a sphingosine-1-phosphate receptor 1 (S1P₁) and S1P₅ agonist.¹ It induces GTPγS binding in cell membranes expressing human S1P₁ or S1P₅ (EC₅₀s = 0.41 and 11 nM, respectively) but not cell membranes expressing S1P₂ or S1P₃ receptors (EC₅₀s = >10,000 nM for both). Ozanimod (0.2 mg/kg) reduces the number of peripheral lymphocytes in rats. It reduces disease severity and the number of circulating lymphocytes in a mouse model of experimental autoimmune encephalomyelitis (EAE). Ozanimod (0.3 and 1 mg/kg) reduces disease severity and body weight loss in a mouse model of TNBS-induced colitis. Formulations containing ozanimod have been used in the treatment of relapsing multiple sclerosis and ulcerative colitis.

Reference

1. Scott, F.L., Clemons, B., Brooks, J., *et al.* Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P₁) and receptor-5 (S1P₅) agonist with autoimmune disease-modifying activity. *Br. J. Pharmacol.* **173**(11), 1778-1792 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM